Natalizumab is a monoclonal antibody against 4 integrins.
The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated with natalizumab was reclassified as JC virus-related progressive multifocal leukoencephalopathy.
|Virus DNA was in the serum 3 after the initiation of open-label natalizumab monotherapy |
|New England Journal of Medicine|
Dr Van Assche and colleagues conducted an analysis of frozen serum samples after natalizumab monotherapy.
The investigators showed that JC virus DNA had appeared in the serum 3 months after the initiation of open-label natalizumab monotherapy.
In addition, the team identified DNA of the JC virus in the serum 2 months before the appearance of symptomatic progressive multifocal leukoencephalopathy.
The investigative team noted that there was staining of the brain lesion for polyomavirus.
Dr Van Assche's team concluded, “This case report, along with 2 others, suggests that anti-4-integrin therapy can result in JC virus-induced progressive multifocal leukoencephalopathy."